Anticoagulation in COVID-19

Charlotte A. Bradbury; Zoe McQuilten

doi:10.1016/S0140-6736(21)02503-4

Anticoagulation in COVID-19

Charlotte A. Bradbury, Zoe McQuilten

Research output: Contribution to journal › Comment / Debate › Other › peer-review

Original language	English
Pages (from-to)	5-7
Number of pages	3
Journal	The Lancet
Volume	399
Issue number	10319
DOIs	https://doi.org/10.1016/S0140-6736(21)02503-4
Publication status	Published - 1 Jan 2022

Access to Document

10.1016/S0140-6736(21)02503-4

Cite this

@article{247f7ebbec4548e2bae0e6cf7cb4ed1f,

title = "Anticoagulation in COVID-19",

author = "Bradbury, {Charlotte A.} and Zoe McQuilten",

note = "Funding Information: ZM declares no competing interests. Related to the topic, CAB has received speaker's fees from Bayer for non-promotional education and conference funding from Bayer to present research data unrelated to rivaroxaban. Unrelated to the topic, CAB has received speaker's fees from Amgen, Bristol Myers Squibb/Pfizer Alliance, Janssen, Eli Lilly, and Novartis; support to attend conferences from Amgen and Novartis; and advisory fees from Ablynx, Bristol Myers Squibb/Pfizer Alliance, Lilly, Novartis, and Portola.",

year = "2022",

month = jan,

day = "1",

doi = "10.1016/S0140-6736(21)02503-4",

language = "English",

volume = "399",

pages = "5--7",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "10319",

}

TY - JOUR

T1 - Anticoagulation in COVID-19

AU - Bradbury, Charlotte A.

AU - McQuilten, Zoe

N1 - Funding Information: ZM declares no competing interests. Related to the topic, CAB has received speaker's fees from Bayer for non-promotional education and conference funding from Bayer to present research data unrelated to rivaroxaban. Unrelated to the topic, CAB has received speaker's fees from Amgen, Bristol Myers Squibb/Pfizer Alliance, Janssen, Eli Lilly, and Novartis; support to attend conferences from Amgen and Novartis; and advisory fees from Ablynx, Bristol Myers Squibb/Pfizer Alliance, Lilly, Novartis, and Portola.

PY - 2022/1/1

Y1 - 2022/1/1

UR - http://www.scopus.com/inward/record.url?scp=85121923517&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(21)02503-4

DO - 10.1016/S0140-6736(21)02503-4

M3 - Comment / Debate

C2 - 34921757

AN - SCOPUS:85121923517

SN - 0140-6736

VL - 399

SP - 5

EP - 7

JO - The Lancet

JF - The Lancet

IS - 10319

ER -

Anticoagulation in COVID-19

Access to Document

Other files and links

Cite this